Annals of Oncology
Journal Abbreviation: ANN ONCOL
ISSN: 0923-7534
eISSN: 1569-8041
Publisher: Elsevier
Publications (160)
Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triplenegative breast cancer, TNBC) (PM(Cb)) for patients (pts) with highrisk early breast cancer (BC) (2020)
Schneeweiss A, Moebus V, Tesch H, Klare P, Denkert C, Kast K, Hanusch C, et al.
Conference contribution
EPIK-B3: A phase III, randomised, double-blind (DB), placebo (PBO)-controlled study of alpelisib (ALP) plus nab-paclitaxel (nabPTX) in advanced triple-negative breast cancer (TNBC) with either PIK3CA mutation or phosphatase and tensin homolog (PTEN) loss without PIK3CA mutation (2020)
Sharma P, Farooki A, Fasching P, Loi S, Peterson K, Prat A, Tripathy D, et al.
Conference contribution
GeparX: Denosumab (Dmab) as add-on to different regimen of nab-paclitaxel (nP)-anthracycline based neoadjuvant chemotherapy (NACT) in early breast cancer (BC): Subgroup analyses by RANK expression and HR status (2020)
Link T, Blohmer JU, Just M, Untch M, Stoetzer O, Fasching P, Schneeweiss A, et al.
Conference contribution
Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332) (2020)
Hauke J, Ernst C, Fasching P, Jackisch C, Seither F, Klare P, Rhiem KE, et al.
Conference contribution
Real-world analysis of dabrafenib plus trametinib in patients with BRAFV600-mutated melanoma brain metastases (2020)
Berking C, Schadendorf D, Weichenthal M, Eigentler T, Mohr P, Schober K, Kiecker F, et al.
Conference contribution
Efficacy and safety of lanreotide autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumours (NETs): CLARINET FORTE study results (2020)
Pavel ME, Cwikla JB, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Thanh XMT, et al.
Conference contribution
Safety analysis of the run-in phase (1st and 2nd cohort) of the IMMUNIB trial (AIO-HEP-0218/ass) - An open-label, single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced stage HCC (2020)
Vogel A, Mueller DW, De Toni E, Siegler GM, Lindig U, Mueller T, Schultheiss M, et al.
Conference contribution
Pooled analysis of patient (pt)-reported quality of life (QOL) in the MONALEESA (ML)-2,-3, and-7 trials of ribociclib (RIB) plus endocrine therapy (ET) to treat hormone receptore-positive, HER2-negative (HR+/HER2L) advanced breast cancer (ABC) (2020)
Fasching P, Bardia A, Nusch A, Jerusalem G, Chan A, El Saghir N, Alba E, et al.
Conference contribution
Comparative effectiveness of ribociclib plus fulvestrant (RIB plus FUL) versus palbociclib plus letrozole (PAL plus LET) as first-line (1L) treatment (Tx) of HR+/HER2L advanced breast cancer (ABC) assessed by matching-adjusted indirect comparison (MAIC) (2020)
Fasching P, Delea T, Lu YS, Deboer R, Hurvitz SA, Moynahan A, Chandiwana D, et al.
Conference contribution
Assessment of prognostic and predictive value of FGFR alterations (FGFRa) in a real-world cohort of patients (pts) with high-risk pT1 non-muscle-invasive bladder cancer (NMIBC) (2020)
Breyer J, Monga M, Mayr R, Otto W, Burger M, Eckstein M, Stöhr R, et al.
Conference contribution